{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-018791","form_type":"8-K","ticker":"IMNN","cik":"0000749647","company_name":"Imunon, Inc.","filed_at":"2024-05-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:21.899464+00:00","generated_at":"2026-06-02T02:57:56.926500+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Imunon Q1 net loss $4.9M ($0.52/shr), appoints Stacy Lindborg as CEO; OVATION 2 data expected mid-2024","bullets":["Net loss of $4.9M ($0.52/shr) vs $5.6M ($0.68/shr) in Q1 2023; operating expenses down 12% to $5.0M.","Cash and investments $9.8M; believes funding sufficient through end of 2024.","Stacy Lindborg appointed President and CEO effective May 13, 2024; previously a director and Co-CEO of BrainStorm.","OVATION 2 Study of IMNN-001 in advanced ovarian cancer: interim PFS delay ~3 months, OS improvement ~9 months; final readout mid-2024.","FDA cleared IND for IMNN-101 seasonal COVID booster; Phase 1 starting Q2 2024. Received $1.3M non-dilutive from NJ NOL sale."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-018791","json":"https://secwatch.observer/filing/0001493152-24-018791.json","markdown":"https://secwatch.observer/filing/0001493152-24-018791.md","text":"https://secwatch.observer/filing/0001493152-24-018791.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/749647/000149315224018791/0001493152-24-018791-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/749647/000149315224018791/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T02:57:56.926500+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8412bc7ebc3bef5d896a67dae89be7978ec1bc94","claim":"Imunon, Inc. reported financial results for quarter ended March 31, 2024.","evidence_excerpt":"On May 13, 2024, Imunon, Inc. issued a press release reporting its financial results for the quarter ended March 31, 2024.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/749647/000149315224018791/0001493152-24-018791-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"quarter ended March 31, 2024"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}